Cohort profile update: the main and new findings from the SaMi-Trop Chagas cohort

• Published in: Revista do Instituto de Medicina Tropical de São Paulo
• Main Authors: Oliveira, Claudia Di Lorenzo, Cardoso, Clareci Silva, Baldoni, Nayara Ragi, Natany, Larissa, Ferreira, Ariela Mota, de Oliveira, Lea Campos, Nunes, Maria do Carmo Pereira, Quintino, Nayara Dornela, Bierrenbach, Ana Luiza, Buss, Lewis F., Haikal, Desiree Sant’Ana, Cunha, Edecio, Ribeiro, Antonio Luiz Pinho, Sabino, Ester Cerdeira
• Format: Text
• Language: English
• Published: Instituto de Medicina Tropical de São Paulo 2021
• Subjects: Original Article; sami
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494491/; http://www.ncbi.nlm.nih.gov/pubmed/34586309; https://doi.org/10.1590/S1678-9946202163075

The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-seropositive patients were enrolled from the primary care Telehealth service in Minas Gerais State, Brazil. The eligibility criterium for the second visit was the participation in the baseline evaluation. Of 1,959 participants at the baseline assessment, 1,585 (79.9%) returned after two years for the second evaluation. The mortality rate was 6.7%, but varied from 0.9% to 18.2% when it was stratified by certain clinical characteristics. A lower age-adjusted NT-Pro-BNP level (less than 300) and a prior benznidazole treatment were associated with lower mortality. There was an improvement in most quality of life domain scores. Participants have also reported fewer signs and symptoms and greater use of medication. The second follow-up visit will be complete in Oct 2021.